Zynerba Pharmaceuticals, Inc (NASDAQ: ZYNE) gave investors an update on its clinical program this week. Like weeds, specialty pharmaceutical companies have sprung up and engaged in developing commercially viable therapies based on cannabinoids, a primary compound found in cannabis.
In light of the impending results from Zynerba, below is a list of prominent cannabinoid product platforms in the clinical stage.
Zynerba expects top-line results from two trials in August. The STAR-1 trial, exploring its ZYN002 treatment for adult epilepsy, should see